Â鶹´«Ã½Ó³»­

Â鶹´«Ã½Ó³»­

Explore the latest content from across our publications
Join The Â鶹´«Ã½Ó³»­

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Examining factors influencing progression of inclusion body myositis: analysis of an international patient-reported registry
Neuromuscular and Clinical Neurophysiology (EMG)
Neuromuscular and Clinical Neurophysiology (EMG) Posters (7:00 AM-5:00 PM)
108
To examine factors that may influence the progression of sporadic inclusion body myositis (IBM).

IBM is the most common idiopathic inflammatory myopathy over the age of 50. This is a gradually progressive debilitating disease with significant impairment of hand function and mobility. There is limited longitudinal data describing the natural history of this disease.

The IBM Registry at Yale is a large online database which collects patient-reported demographics and clinical data on IBM. We included patients with IBM who entered data on their disease progression for over 1 year and analyzed data over 2-years. We used a linear mixed-effect model with a random intercept for this preliminary analysis to examine the effect of age of onset, gender, and exercise on IBM disease progression, based on the patient-reported IBM-functional rating scale (IBMFRS) score.
Ninety-one patients with IBM (62 male) were included in this study to date. The average age of symptom onset was 59.3 ± 7 years. Baseline IBMFRS score was 27.7 ± 6.3, which deteriorated to 23.6 ± 8.2 over the course of 2 years. Patients with age of onset before the age of 60 were more likely to have faster disease progression (p-value <0.001). Exercise appeared to have a potential beneficial effect (p-value 0.001), whereas no significant difference was noted between genders.

Exercise may have a beneficial effect on IBM disease progression, and further studies are warranted. The impact of other potential confounders, such as medication use, associated co-morbidities, and their interactions, needs to be further examined. 

Authors/Disclosures
Bhaskar Roy, MD, FÂ鶹´«Ã½Ó³»­ (Yale University)
PRESENTER 		Dr. Roy has received personal compensation in the range of $500-$4,999 for serving as a Consultant for argenx. Dr. Roy has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Sanofi. Dr. Roy has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Takeda. Dr. Roy has or had stock in Cabaletta bio. .Dr. Roy has or had stock in Pfizer.Dr. Roy has or had stock in CAVA. The institution of Dr. Roy has received research support from Abcuro Pharmaceuticals. The institution of Dr. Roy has received research support from Immunovant. The institution of Dr. Roy has received research support from argenx.
Richard J. Nowak, MD (Yale University School of Medicine) Dr. Nowak has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion . Dr. Nowak has received personal compensation in the range of $500-$4,999 for serving as a Consultant for argenx. Dr. Nowak has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UCB. Dr. Nowak has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Immunovant . Dr. Nowak has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Cabaletta Bio . Dr. Nowak has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Amgen. Dr. Nowak has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Cour Pharma. Dr. Nowak has received personal compensation in the range of $500-$4,999 for serving as a Consultant for EMD Serono. Dr. Nowak has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Janseen . The institution of Dr. Nowak has received research support from UCB. The institution of Dr. Nowak has received research support from Alexion . The institution of Dr. Nowak has received research support from Janseen. The institution of Dr. Nowak has received research support from Immunovant . The institution of Dr. Nowak has received research support from argenx. The institution of Dr. Nowak has received research support from Amgen. Dr. Nowak has a non-compensated relationship as a Member of the Board of Directors with Myasthenia Gravis Foundation of America (MGFA) that is relevant to Â鶹´«Ã½Ó³»­ interests or activities.
No disclosure on file
No disclosure on file